


I claim:

1. A compound of the following formula:



5

wherein R₂ and R₄ are each independently H, alkyl, halogen;
R₁₅ and R₁₆ are each independently H, alkyl, acyl, alkoxy, aryl, amino, halogen;
and pharmaceutically acceptable salts and prodrugs thereof.

10 2. A compound of claim 1, wherein R₂ is halogen, and R₄ is H.

3. A compound of claim 1, wherein R₂ is H and R₄ is halogen.

4. A compound of claim 1, wherein R₂ and R₄ are H, and R₁₅ is amino.

15

5. A compound of claim 1, wherein R₂ is H or halogen; R₄ is H or halogen; and R₁₅ is alkoxy.

6. A compound of claim 1, wherein R₂, R₄, R₁₅ are H or halogen.

20

7. A compound of claim 1, wherein R₂, R₄ are H or halogen; R₁₅ is alkyl.



8. A compound of claim 1, wherein R₂ is H, R₄ is H, R₁₅ is NR₁R₂, and R₁₆ is H.

9. A compound of claim 1, wherein R₁₆ is HET.




5

10. A compound of claim 9, wherein HET is pyrrolidine, morpholine.


11. A compound of claim 1 having the following structure:




10



5





12. A hormone replacement therapy regimen comprising:

co-administering a therapeutically effective amount of a combination of

5 mammalian estrogen and a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a woman having reduced levels of endogenous estrogen.

12. A method for inhibiting or treating coronary heart disease, cardiovascular disease, comprising:

10 administering a therapeutically effective amount of a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.

13. A method of inhibiting or treating osteoporosis, comprising:

administering a therapeutically effective amount of a compound of any one of

15 claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.

14. A method of inhibiting or treating gastrointestinal disease, comprising:

administering a therapeutically effective amount of a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.

20

15. A method of inhibiting or treating amebic infections, including giardiasis, comprising:

administering a therapeutically effective amount of a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.